secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eledon Pharmaceuticals, Inc. (ELDN)
CIK:        0001404281
Form:       8-K
Filed at:   2025-08-14T23:59:59+00:00
Accession:  0001193125-25-180820
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 2.02, 4.02, 9.01
LLM model:  deepseek-v4-flash:cloud

Eledon Pharmaceuticals Restates Prior Financials and Reports Q2 2025 Results
----------------------------------------------------------------------------

- Restated financial statements for fiscal years 2023 and 2024 and Q1 2025 due to misclassification of Series X and X1 preferred stock; will reclassify as temporary equity.
- Identified a material weakness in internal control over financial reporting related to accounting for equity instruments; controls and disclosure controls were not effective.
- Reported Q2 2025 net loss of $11.2 million ($0.13 per share) and cash and short-term investments of $107.6 million as of June 30, 2025.
- Updated Phase 1b data for tegoprubart showed mean 12-month eGFR of ~68 mL/min/1.73m²; Phase 2 BESTOW topline expected November 2025.
- Company expects current cash to fund operations to the end of 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1404281/000119312525180820/0001193125-25-180820-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1404281/000119312525180820/eldn-20250811.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-180820

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer